ReDO_DB: the repurposing drugs in oncology database

Pantziarka, Pan; Verbaanderd, Ciska; Sukhatme, Vidula; Capistrano, I. Rica; Crispino, Sergio; Gyawali, Bishal; Rooman, Ilse; Nuffel, Van; Meheus, Lydie; Sukhatme, Vikas P.; Bouche, Gauthier

doi:10.3332/ecancer.2018.886

Cited by 106 publications

(94 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EMA in Europe and the NIH and the FDA in the USA have already launched DR programs to identify new uses for existing pipeline medications developed by the pharmaceutical industry . Furthermore, the ReDO project is an ongoing collaborative project that has focused exclusively on the potential use of approved noncancer medications as sources of new anticancer therapeutics . An open‐access version is available online via http://www.redo-project.org/db.…”

Section: Resultsmentioning

confidence: 99%

“…This approach is used to identify licensed noncancer drugs with published evidence of anticancer activity using PubMed, MEDLINE and databases of clinical trials, such as ClinicalTrials.gov or University Hospital Medical Information Network Clinical Trials Registry (UMIN‐CTR), which is used mainly in Japan, chemical databases (DrugQuest) and other large‐scale databases . One example of successful use of literature‐based DR in cancer is the Repurposing Drugs in Oncology (ReDO) project, which was designed to rapidly identify new and effective cancer treatments characterized by low toxicity and cost‐effectiveness .…”

Section: Approach For Drug Repositioningmentioning

confidence: 99%

“…Furthermore, prior extensive investigations of the pharmacokinetic and pharmacodynamic characteristics of drugs can allow researchers to avoid studies assessing drug dosage, safety and toxicity . In a previous report, Pantziarka et al summarized the advantages of DR as follows: availability of pharmacokinetic, pharmacodynamics and posology data; knowledge of safety, toxicity and adverse events; clinical experience derived from the original indications; widespread availability worldwide; understanding of the mechanisms of action and molecular targets of the drug; and low cost. In most cases, DR can allow researchers to avoid carrying out preclinical tests and phase I trials, thereby reducing the cost of the drug development process (Figure ).…”

Section: Advantages Of Drug Repositioningmentioning

confidence: 99%

See 2 more Smart Citations

Drug repositioning in cancer: The current situation in Japan

et al. 2020

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide, and the incidence continues to increase. Despite major research aimed at discovering and developing novel and effective anticancer drugs, oncology drug development is a lengthy and costly process, with high attrition rates. Drug repositioning (DR, also referred to as drug repurposing), the process of finding new uses for approved noncancer drugs, has been gaining popularity in the past decade. DR has become a powerful alternative strategy for discovering and developing novel anticancer drug candidates from the existing approved drug space. Indeed, the availability of several large established libraries of clinical drugs and rapid advances in disease biology, genomics/transcriptomics/ proteomics and bioinformatics has accelerated the pace of activity-based, literaturebased and in silico DR, thereby improving safety and reducing costs. However, DR still faces financial obstacles in clinical trials, which could limit its practical use in the clinic. Here, we provide a brief review of

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Approach For Drug Repositioningmentioning

confidence: 99%

Section: Advantages Of Drug Repositioningmentioning

confidence: 99%

See 1 more Smart Citation

Drug repositioning in cancer: The current situation in Japan

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The completion of repurposing drug in oncology (ReDO) project has provided evidence for the new uses of 6 drugs for breast cancer. Originally these were discovered for indications other than breast cancer [137]. These drugs include mebendazole (anti-helminthic), cimitedine (anti-acid), nitroglycerins (heart attack preventing), itraconazole (anti-fungal), and diclofenac (anti-inflammatory).…”

Section: Future Perspectives and Challengesmentioning

confidence: 99%

Drug repurposing for breast cancer therapy: Old weapon for new battle

Aggarwal

Verma

Aggarwal

et al. 2021

Seminars in Cancer Biology

110

View full text Add to dashboard Cite

Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development. Repositioning of old, clinically approved, off patent non-cancer drugs with known targets, into newer indication is like using old weapons for new battle. The advances in genomics, proteomics and information computational biology has facilitated the process of drug repurposing. Repositioning approach not only fastens the process of drug development but also offers more effective, cheaper, safer drugs with lesser/known side effects. During the last decade, drugs such as alkylating agents, anthracyclins, antimetabolite, CDK4/6 inhibitor, aromatase inhibitor, mTOR inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment. The repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer. The literature review suggest that serendipity plays a major role in the drug development. This article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment. The strategies as well as several examples of repurposed drugs are provided. The challenges associated with drug repurposing are discussed. Current breast cancer therapyUnlike a decade ago, clinicians today have multiple choices for breast cancer treatment depending on the size, stage, grade, metastatic behavior, aggressiveness and intrinsic molecular subtyping of tumor, age, menopausal status, overall health, comorbidities, and preferences of the patient [9-13]. Chemotherapy, hormone therapy, immunotherapy, radiotherapy, and surgery are the common modalities for breast cancer [10,14]. Primary choice of treatment usually includes surgery with the aim of complete resection of the major tumor mass on the first hand. Breast conserving (lumpectomy) and breast reconstruction surgeries, mastectomy or lymph node dissections are performed initially in the breast cancer patients [15]. Surgery may be preceded with the systemic neoadjuvant therapies in order to shrink the tumor for effective surgery and to maximize breast conservation. For example, in HER2+ cases, Trastuzumab (Herceptin) and Pertuzumab (Perjeta)

show abstract

“…Due to this lack of commercial interest, new uses for off-patent and generic medicines are mainly studied in independent clinical trials initiated and led by researchers from academia, research institutes or collaborative groups (20). These trials are typically supported by public and philanthropic funds and aim to answer clinical questions that have an important impact on public health and patient needs but that are not addressed by industry-led trials (21,22).…”

Section: Introductionmentioning

confidence: 99%

New Mechanisms to Fund Independent Clinical Trials for Repurposing Off-Patent or Generic Medicines

Verbaanderd

Rooman

Huys

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Finding new therapeutic uses for approved, off-patent or generic medicines could lead to safe, affordable and timely new treatment options for patients with high medical needs. However, due to a lack of economic incentives, pharmaceutical developers are rarely interested to invest in this type of research. Consequently, potential new uses for off-patent or generic medicines are mainly studied in independent proof-of-concept clinical trials initiated and led by researchers from academia, research institutes or collaborative groups. Yet, these researchers need additional financial support to conduct expensive phase III clinical trials to confirm the results from exploratory research. In this study, scientific and grey literature was searched to identify and evaluate new mechanisms for funding clinical trials with repurposed medicines. Semi-structured interviews were conducted with 16 European stakeholders with expertise in clinical research, funding mechanisms and/or drug repurposing between November 2018 and February 2019 to consider the future perspectives of applying new funding mechanisms. Traditional grant funding awarded by government and philanthropic organisations or companies is well known and widely implemented in all research fields. In contrast, the application potential of newer mechanisms to fund independent clinical research, such as social impact bonds or crowdfunding, is not yet known. Interviewees stated that there is a substantial need for additional financial support in health research, especially in disease domains where there is limited commercial interest. However, the implementation of new funding mechanisms is facing several practical and financial challenges, such as a lack of expertise and guidelines, high transaction costs and difficulties to measure health outcomes. Furthermore, increased collaboration and centralisation at a European and international level is recommended to make clinical research more efficient and reduce the need for additional funding. New funding mechanisms to support clinical research may become more important in the future, but the unresolved issues warrant further exploration in pilot projects.

show abstract

ReDO_DB: the repurposing drugs in oncology database

Cited by 106 publications

References 25 publications

Drug repositioning in cancer: The current situation in Japan

Drug repositioning in cancer: The current situation in Japan

Drug repurposing for breast cancer therapy: Old weapon for new battle

New Mechanisms to Fund Independent Clinical Trials for Repurposing Off-Patent or Generic Medicines

Contact Info

Product

Resources

About